The KLOW peptide component research: four specification dossiers, one combination gap

Start here: what the KLOW research record actually is

KLOW peptide is a four-arm co-formulation. Its research record is, by necessity, a compound of four separate component dossiers: the KPV literature, the GHK-Cu literature, the BPC-157 literature, and the TB-500 / thymosin beta-4 literature. These are independent bodies of peer-reviewed work. Their intersection — the KLOW blend itself — has zero controlled in-vivo or human studies. This section documents each arm in turn, attributes findings to their source component, and marks every blend-level inference as an extrapolation.

The primary keyword for this domain, KLOW, appears throughout. The word 'klow' as a compound term enters the literature only as a vendor name for this co-formulation; the science underneath it is the science of its four arms, which is where the evidence base lives.

KLOW

KLOW as a named blend is a co-formulated research product. Its biological rationale is assembled from four mechanistically non-overlapping targets: innate-immune transcription (KPV via NF-kappaB / MAPK), extracellular-matrix and antioxidant gene programs (GHK-Cu), angiogenesis and tissue repair (BPC-157 via VEGFR2), and cell migration via G-actin sequestration (TB-500 / thymosin beta-4). The rationale is scientifically coherent. Whether the blend acts synergistically, additively, or in ways that differ from each component alone has not been tested.

KPV arm: PepT1-mediated anti-inflammatory signaling

KPV (Lys-Pro-Val, MW 342.44 Da, CAS 67727-97-3) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH). In human intestinal epithelial cells (Caco2-BBE, HT29-Cl.19A) and Jurkat T cells, nanomolar KPV inhibits NF-kappaB p65/RelA nuclear import and MAPK (ERK/p38) activation, reducing TNF-alpha, IL-6, IL-1beta, and IL-8 output ^[3]. The mechanism of cellular uptake is through PepT1 (SLC15A1), the intestinal di/tripeptide transporter upregulated in inflamed mucosa; Km ~160 microM has been reported, making inflamed gut tissue a preferred delivery target relative to healthy tissue.

In mouse DSS- and TNBS-induced colitis models, oral KPV (100 microM in drinking water) reduced colitis severity ^[3]. Hyaluronic-acid-functionalized nanoparticle delivery of KPV in a chitosan/alginate hydrogel showed a much stronger capacity to prevent mucosal damage and downregulate TNF-alpha in DSS mice versus non-targeted formulations, establishing targeted colonic delivery as a viable strategy ^[11]. A 2026 advance demonstrated self-immolative conjugates that improved oral bioavailability of peptides across the intestinal epithelial barrier, addressing the central translational challenge for oral KPV-class peptides ^[15].

No controlled KPV monotherapy trial has reached regulatory approval. Human data are restricted to delivery pilots and an IBD-program lineage.

GHK-Cu arm: transcriptomic modulation and matrix synthesis

GHK-Cu (Gly-His-Lys complexed 1:1 to copper(II), MW 402.92 Da, CAS 89030-95-5) is naturally occurring; endogenous plasma GHK concentration falls from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 ^[4]. Pickart's 2015 review documented that GHK-Cu stimulates procollagen I and IV synthesis, dermatan sulfate, chondroitin sulfate, and the proteoglycan decorin; topical GHK-Cu increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid in a placebo-controlled comparison ^[4].

A 2018 Connectivity Map analysis showed GHK modulates approximately 31.2% of human genes at a ≥50% change threshold — with strong stimulation of the ubiquitin-proteasome system (41 gene loci), DNA repair, antioxidant defense, and anti-inflammatory gene sets; the widely cited '~4,000 gene' figure is an extrapolation from this analysis and should be qualified accordingly ^[5].

Human ex-vivo skin-penetration experiments with GHK-Cu topically applied to dermatomed skin recorded a permeability coefficient of 2.43 ± 0.51 × 10^−4 cm/h, with 136 microg/cm^2 permeating over 48 hours and a 97 microg/cm^2 dermal depot ^[10]. In human epidermal cells, liposomal GHK-Cu produced 48.9% elastase inhibition with no cytotoxicity ^[13]. A biotinylated GHK scaffold demonstrated antioxidant and antiglycant activity against amyloid-beta and acrolein adducts in vitro, extending the observed biology to neurodegeneration-relevant chemistry ^[12].

Rat HPLC pharmacokinetic data document rapid plasma degradation of free GHK to the dipeptide HK after intravenous administration ^[8] — the closest available PK datum; no validated human half-life for GHK-Cu exists.

GHK-Cu does not have an approved systemic indication. Its robust evidence base is topical and cosmetic; the systemic pharmacology observed in cell and animal studies informs mechanistic understanding but does not constitute human clinical evidence.

BPC-157 arm: VEGFR2 angiogenesis and tissue repair

BPC-157 (Body Protection Compound 157, GEPPPGKPADDAGLV, MW 1419.53 Da, CAS 137525-51-0) is a synthetic 15-amino-acid peptide derived from a partial sequence of a gastric-juice protein. It activates the VEGFR2 / PI3K / Akt / eNOS angiogenic axis, upregulates the growth-hormone receptor in tendon fibroblasts, and modulates the nitric-oxide (NO) system via a pathway partly resistant to L-NAME.

In Wistar rats with a fully transected Achilles tendon, IP BPC-157 at 10 microg, 10 ng, or 10 pg per rat accelerated biomechanical, functional, microscopic, and macroscopic healing and stimulated tendocyte outgrowth in vitro ^[2]. A 2026 rat model demonstrated resolution of a tracheocutaneous fistula by BPC-157 via the NO system, extending the documented tissue-repair mechanism ^[14].

The only human BPC-157 IV data are from a 2025 safety pilot: 10 mg on day 1 and 20 mg on day 2 (1-hour infusion each) in two healthy adults (58-year-old male, 68-year-old female) were well tolerated with no observed adverse events and no changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers ^[6]. Two subjects; not an efficacy trial. The remaining human evidence is case series only. BPC-157 was designated FDA 503A category 2 in the bulk-substances review, meaning it may not be used in 503A compounding.

A 2026 Sports Medicine systematic review includes BPC-157 and TB-500 among unapproved musculoskeletal peptides showing favorable animal-model outcomes but scarce human safety data; the review notes these compounds operate largely outside regulatory oversight ^[7].

TB-500 arm: G-actin sequestration and wound closure

TB-500 (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, Ac-LKKTETQ, MW 889.02 Da) is a synthetic N-acetylated heptapeptide corresponding to the LKKTET actin-binding motif of the full-length, 43-amino-acid native protein thymosin beta-4 (Tbeta4). This distinction — TB-500 is the short fragment; Tbeta4 is the full-length protein — is a critical qualifier on every cited efficacy finding.

Most foundational efficacy data are for native Tbeta4. In a rat full-thickness wound model, Tbeta4 increased re-epithelialization by 42% at 4 days and 61% at 7 days versus saline, wound contraction by ≥11% by day 7, and elevated collagen deposition and angiogenesis; as little as 10 pg stimulated keratinocyte migration 2–3-fold ^[1]. These are native-protein results. Whether the TB-500 fragment, which lacks the full-length protein's integrin-linked-kinase activation and epicardial-progenitor-mobilizing domains, reproduces these effects is not established by controlled data.

An LC-MS doping-control study characterized the TB-500 fragment identity as Ac-LKKTETQ, detected parent peptide and metabolites in equine plasma and urine at LOD 0.01–0.02 ng/mL, and confirmed TB-500 is a distinct analytical entity from Tbeta4 ^[9]. Thymosin beta-4 is prohibited at all times under WADA S2; TB-500 implicates the same prohibition ^[7][9].

The 2026 musculoskeletal peptide review ^[7] notes scarce human safety data for TB-500 and uncertain clinical translation from animal models.